AbbVie had its Relative Strength (RS) Rating stock upgraded from 66 to 71 Thursday -- a welcome improvement, but still short of the 80 or better score you look for.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
Over 100 years of market history reveals that the best stocks often have an 80 or higher RS Rating as they launch their largest runs. See if AbbVie stock can continue to rebound and hit that benchmark.
Looking For The Best Stocks To Buy And Watch? Start Here
Is AbbVie Stock A Buy?
AbbVie stock is working on a cup-with-handle pattern with a 168.11 entry. See if the medical stock can break out in volume at least 40% higher than normal. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Although earnings and sales growth came in at -14% and -5%, respectively, in the latest report, that marked acceleration for both the top and bottom lines. The drugmaker is expected to release its next quarterly numbers on or around Oct. 27.
AbbVie stock earns the No. 6 rank among its peers in the Medical-Ethical Drugs industry group. Zoetis and Novartis ADR are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
